Source: https://www.wipo.int/amc/en/domains/decisions/html/2006/d2006-0229.html
Timestamp: 2019-04-19 18:16:19+00:00

Document:
The Complainant is F. Hoffmann-La Roche AG, Basel, Switzerland, represented a legal representative, Switzerland.
The Respondent is Brito Meyer, Rio de Janeiro, Brazil.
The disputed domain name <buytamiflu.name> is registered with Wild West Domains, Inc.
The Complaint was filed with the WIPO Arbitration and Mediation Center (the “Center”) on February 22, 2006. On February 23, 2006, the Center transmitted by email to Wild West Domains, Inc. a request for registrar verification in connection with the domain name at issue. On February 23, 2006, Wild West Domains, Inc. transmitted by email to the Center its verification response confirming that Respondent is listed as the registrant and providing the contact details for the administrative, billing, and technical contact. The Center verified that the Complaint satisfied the formal requirements of the Uniform Domain Name Dispute Resolution Policy (the “Policy”), the Rules for Uniform Domain Name Dispute Resolution Policy (the “Rules”), and the WIPO Supplemental Rules for Uniform Domain Name Dispute Resolution Policy (the “Supplemental Rules”).
In accordance with the Rules, paragraphs 2(a) and 4(a), the Center formally notified Respondent of the Complaint, and the proceedings commenced on March 8, 2006. In accordance with the Rules, paragraph 5(a), the due date for Response was March�28,�2006. Respondent did not submit any response. Accordingly, the Center notified Respondent’s default on March 29, 2006.
The Center appointed Torsten Bettinger as the sole panelist in this matter on April�3,�2006. The Panel finds that it was properly constituted. The Panel has submitted the Statement of Acceptance and Declaration of Impartiality and Independence, as required by the Center to ensure compliance with the Rules, paragraph 7.
Complainant is together with its affiliated companies one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics and having global operations in more than 100 countries. Complainant owns a number of trademark registrations protecting the mark TAMIFLU in numerous countries worldwide, inter alia international registrations No. 713623 TAMIFLU, registered on June 3, 1999, in class 5 and international registration No. 727329 TAMIFLU & device, registered on February 7, 2000, in class 5.
Complainant submitted screen shots of Respondent’s web page at “www.buytamiflu.name” that show that use of the domain name redirects Internet users to a website that offer advertisements for a variety of pharmaceuticals which compete with Complainant’s products.
In reference to the element in paragraph�4(a)(i) of the Policy, Complainant argues that the word “buy” is descriptive and therefore does not eliminate the similarity between Complainant’s trademark TAMIFLU and the disputed domain name.
In reference to the element in paragraph�4(a)(ii) of the Policy, Complainant contends that none of the situations described in paragraph�4(c) of the Policy can be established in this case. Complainant states that Respondent has no authorization or licence to use the TAMIFLU trademark in his domain name and that the use of Complainant’s trademark in order to redirect Internet users interested in Complainant’s goods to sites that offer links to competing websites is not a use in connection with a bona fide offering of goods and services pursuant to Policy,�paragraph�4(c)(i), nor a legitimate noncommercial or fair use pursuant to Policy,�paragraph�4(c)(iii).
In reference to the element in paragraph�4(a)(iii) of the Policy, Complainant asserts that there is no reason for Respondent to use Complainant’s mark in the disputed domain name other than to use it to attract the Internet users to Respondent’s website for commercial gain. Respondent alleges that by using TAMIFLU, Respondent is creating a likelihood of confusion with Complainant’s mark as to the source, sponsorship, affiliation or endorsement of Respondent’s website and the products offered on the website.
The test of confusing similarity under the Policy is confined to a comparison of the disputed domain name and the trademark alone, independent of the products for which the domain name is used or other marketing and use factors, usually considered in trademark infringement (See Arthur Guinness Son & Co. (Dublin) Limited v. Dejan Macesic, WIPO Case No.�D2000-1698 <guiness.com>, Ansell Healthcare Products Inc. v. Australian Therapeutics Supplies Pty, Ltd., WIPO Case No.�D2001-0110 <ansellcondoms.com>, Dixons Group Plc v. Mr. Abu Abdullaah, WIPO Case No.�D2001-0843 <dixons-online.net>, AT&T Corp. v. Amjad Kausar, WIPO Case No.�D2003-0327 <attinternet.com>, <attuniversal.com>, BWT Brands, Inc. and British American Tobacco (Brands), Inc. v. NABR, WIPO Case No.D2001-1480; Britannia Building Society v. Britannia Fraud Prevention, WIPO Case No.�D2001-0505).
The disputed domain name wholly incorporates Complainant’s famous trademark TAMIFLU, used in connection with drugs. The fact that the word “buy” is added to Complainant’s trademark does not eliminate the similarity between Complainant’s trademark and the disputed domain name, as “buy” is a descriptive component of the disputed domain name. In numerous cases, it has been held that a domain name that wholly incorporated a complainant’s registered mark may be sufficient to establish confusing similarity for purposes of the Policy despite the addition of descriptive words to such marks.
It is also well established that the specific top level of a domain name such as “.com”, “.org”, “.net” or “.name” does not affect the domain name for the purpose of determining whether it is identical or confusingly similar (See Magnum Piering, Inc. v. The Mudjackers and Garwood S. Wilson, Sr., WIPO Case No.�D2000-1525; Rollerblade, Inc. v. Chris McCrady, WIPO Case No.�D2000-0429).
The Panel thus finds that the domain name <buytamiflu.name> is confusingly similar to the trademark in which Complainant has exclusive rights and that Complainant has established the requirement of paragraph 4(a)(i) of the Policy.
Paragraph�4(c) of the Policy requires Complainant to prove that Respondent has no right or legitimate interest in the disputed domain name. However, it is consensus view among Panelists that if Complainant makes a prima facie case that Respondent has no rights or legitimate interests, and Respondent fails to show one of the three circumstances under Paragraph�4(c) of the Policy, then Respondent may lack a legitimate interest in the domain name.
Complainant asserted that Respondent has neither a license nor any other permission to use Complainant’s famous trademark TAMIFLU. Respondent has not denied these assertions. The Panel thus finds that Complainant has made a prima facie showing that Respondent has no rights or legitimate interests in the disputed domain name which wholly incorporates Complainant’s mark.
Respondent is not a reseller of Complainant’s TAMIFLU products, but is using Complainant’s trademark to divert Internet users to a parking website with links to competing sites and thus capitalizing on Complainant’s mark. This use is not a bona�fide use pursuant to paragraph�4(c)(i) of the Policy.
Under these circumstances, the Panel takes the view that Respondent has no rights or legitimate interests in the domain name and that the requirement of paragraph�4(a)(ii) is also satisfied.
Respondent registered a domain name which is apart from the descriptive term “buy” identical to Complainant’s trademark. That and the nature of the website Respondent maintains makes it clear that its purpose is to divert traffic intended for Complainant’s site to its own, in the hope that Respondent will earn ad revenue from the diverted traffic.
This qualifies as bad faith under paragraph�4(b)(iv) in that Respondent’s use of the domain name attempts to attract for commercial gain Internet users to Respondent’s website by creating a likelihood of confusion with Complainant’s mark as to the source, sponsorship, affiliation, or endorsement of Respondent’s website or location or of a product or service on Respondent’s website.
Moreover, Respondent’s default in this proceeding reinforces an inference of bad faith. If Respondent had arguments that it acquired the domain name in good faith, and had good faith bases for using the domain name, it should have asserted them.
The Panel therefore concludes that Respondent registered and is using the domain name <buytamiflu.com> in bad faith and that the requirement of paragraph�4(a)(iii) of the Policy is satisfied.
For all the foregoing reasons, in accordance with paragraphs 4(i) of the Policy and 15 of the Rules, the Panel orders that the domain name <buytamiflu.name> be transferred to Complainant.

References: v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v.